Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-03-31
2010-12-07
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07846940
ABSTRACT:
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
REFERENCES:
patent: 3576886 (1971-04-01), Neuworth
patent: 3862332 (1975-01-01), Barnhart et al.
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3959078 (1976-05-01), Guire et al.
patent: 4350160 (1982-09-01), Kolesov
patent: 4366819 (1983-01-01), Kaster
patent: 4368736 (1983-01-01), Kaster
patent: 4624257 (1986-11-01), Berggren et al.
patent: 4722906 (1988-02-01), Guire et al.
patent: 4733665 (1988-03-01), Palmaz
patent: 4739762 (1988-04-01), Palmaz
patent: 4776337 (1988-10-01), Palmaz
patent: 4814470 (1989-03-01), Colin et al.
patent: 4857653 (1989-08-01), Colin et al.
patent: 4917090 (1990-04-01), Berggren et al.
patent: 4917091 (1990-04-01), Berggren et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 4984060 (1991-01-01), Ohmi et al.
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5200534 (1993-04-01), Rao
patent: 5202448 (1993-04-01), Carver et al.
patent: 5229172 (1993-07-01), Cahalan et al.
patent: 5229529 (1993-07-01), Veno et al.
patent: 5234447 (1993-08-01), Kaster et al.
patent: 5248796 (1993-09-01), Chen et al.
patent: 5252805 (1993-10-01), Nakata et al.
patent: 5254580 (1993-10-01), Chen et al.
patent: 5272171 (1993-12-01), Ueda et al.
patent: 5274137 (1993-12-01), Nicolaou et al.
patent: 5278324 (1994-01-01), Kingston
patent: 5279949 (1994-01-01), Nair
patent: 5283253 (1994-02-01), Holton et al.
patent: 5294637 (1994-03-01), Chen et al.
patent: 5294997 (1994-03-01), Ogura et al.
patent: 5300638 (1994-04-01), Farina et al.
patent: 5308641 (1994-05-01), Cahalan et al.
patent: 5339906 (1994-08-01), Fox et al.
patent: 5350800 (1994-09-01), Verhoeven
patent: 5350866 (1994-09-01), Holton et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5380751 (1995-01-01), Chen
patent: 5395850 (1995-03-01), Roth
patent: 5411984 (1995-05-01), Kingston et al.
patent: 5412092 (1995-05-01), Rey et al.
patent: 5415938 (1995-05-01), Cahalan et al.
patent: 5422364 (1995-06-01), Nicolaou
patent: 5440056 (1995-08-01), Klein et al.
patent: 5516770 (1996-05-01), Waranis et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 5891845 (1999-04-01), Myers
patent: 5924997 (1999-07-01), Campbell
patent: 6099562 (2000-08-01), Ding et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6241762 (2001-06-01), Shanley
patent: 6293967 (2001-09-01), Shanley
patent: 6425898 (2002-07-01), Wilson et al.
patent: 6764507 (2004-07-01), Shanley et al.
patent: 7060709 (2006-06-01), Cooperstone et al.
patent: 2003/0170287 (2003-09-01), Prescott
patent: 2004/0024003 (2004-02-01), Asmussen
patent: 2004/0167152 (2004-08-01), Rubino et al.
patent: 2005/0222191 (2005-10-01), Falotico et al.
patent: 2005/0272806 (2005-12-01), Falotico et al.
patent: 0041795 (1981-12-01), None
patent: 0041795 (1981-12-01), None
patent: 590267 (1993-07-01), None
patent: 0950386 (1999-10-01), None
patent: WO 93/10076 (1993-05-01), None
patent: WO 93/19763 (1993-10-01), None
patent: 93/23555 (1993-11-01), None
patent: WO 93/23555 (1993-11-01), None
patent: WO 93/24476 (1993-12-01), None
patent: WO 94/00156 (1994-01-01), None
patent: WO 94/07876 (1994-04-01), None
patent: WO 94/07880 (1994-04-01), None
patent: WO 94/07881 (1994-04-01), None
patent: WO 94/07882 (1994-04-01), None
patent: WO 94/20089 (1994-09-01), None
patent: WO 98/33443 (1998-08-01), None
patent: WO 2004/011000 (2004-02-01), None
patent: WO 2004/026182 (2004-04-01), None
patent: WO 2004/043510 (2004-05-01), None
patent: WO 2004/110302 (2004-12-01), None
Ajroldi et al., “Fluoroelastomers-dependence of relaxation phenomena on compositions”,Polymer30, 2180 (1989).
Arcella, V. et al., “Fluorocarbon Elastomers”,Modern Fluoropolymers, (J. Shires ed.), John Wiley & Sons, New York, pp. 77-87 (1997).
Berk, B.C. et al., “Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After . . . ”,J. Am. College Cardiology17: 111B-117B (1991).
Carrera et al., “Potent Toxicity of 2-Chlorodeoxyadenosine toward Human Monocytes in Vitro and In Vivo”J. Clin. Invest. 86: 1480-1488 (1990).
Carson, D.A. et al., “Specific toxicity of 2-chlorodeoxyadenosine toward resting and prolifcrating human lymphocytcs”,Blood62: 737-743 (1983).
Chang, M. W. et al., “Adenovirus-mediated Over-expression . . . ”J. Clin. Invest. 96: 2260-2268 (1995).
Clowes, A. W. et al. “Suppression by heparin of smooth . . . ”Nature265: 625-626 (1977).
Clowes, A.W. et al. “Kinetics of Cellular Proliferation . . . ”Lab. Invest. 52: 611-616 (1985).
Clowes, A.W. et al., “Kinetics of Cellular Proliferation . . . ”Circ. Res. 58: 839-845 (1986).
Colburn, M.D. et al., “Done responsive suppression of . . . ”J. Vase. Surg. 15: 510-518 (1992).
Currier, J.W. et al.,Circ. 80: 11-66 (1989).
Deroanne, C.F. et al., “Histone deacetylases inhibitors . . . ”,Oncogene21 (3): 427-436 (2002).
Farb, A. et al., “Vascular Smooth Muscle Cell Cytotoxicity . . . ”,Circ. Res. 80: 542-550 (1997).
Ferns, G.A.A. et al., “Inhibition of Neointimal Smooth Muscle Accumulation after Angioplasty . . . ”,Science253: 1129-1132 (1991).
Fukuyama, J. et al., “Tranilast suppresses the vascular intimal hyperplasia after balloon injury . . . ”Eur. J. Pharmacol. 318: 327-332 (1996).
Guyton, J.R. et al., “Inhibition of Rat Arterial Smooth Muscle . . . ”Circ. Res. 46: 625-634 (1980).
Hanson, S.R. et al, “Interruption of acute platelet-dependent thrombosis by the synthetic . . . ”Proc. Natl. Acad. Sci. USA85: 3184-3188 (1988).
Hansson, G.K. et al., “Interferon-γ Inhibits Arterial Stenosis . . . ”Circ. 84: 1266-1272 (1991).
Jonasson, L. et al., “Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury”Proc. Natl. Acad. Sci. 85: 2303 (1988).
Liu, M.W. et al., “Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit”Circ. 81: 1089-1093 (1990).
Lundergan, C.F. et al., “Peptide Inhibition of Myointimal Proliferation by Angiopeptin . . . ”Am. J. Cardiol. 17 (Suppl. B): 132B-136B (1991).
Majesky, M.W. et al., “Heparin Regulates Smooth Muscle S Phase Entry In the Injured Rat Carotid Artery”Circ. Res. 61: 296-300 (1987).
Marx, S.O. et al., “Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation In Vascular Smooth Muscle Cells” Circ. Re
Falotico Robert
Zhao Jonathon Z.
Cordis Corporation
Evens Carl
Kim Jennifer M
LandOfFree
Solution formulations of sirolimus and its analogs for CAD... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solution formulations of sirolimus and its analogs for CAD..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solution formulations of sirolimus and its analogs for CAD... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4163892